CLINICAL TRIALS PROFILE FOR MEXATE-AQ

All Clinical Trials for Mexate-aq

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002798 ↗	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	Eastern Cooperative Oncology Group	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	Gynecologic Oncology Group	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003934 ↗	Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	This randomized phase III trial is studying tretinoin and combination chemotherapy to see how well they work compared to tretinoin, combination chemotherapy, and arsenic trioxide in treating patients with acute promyelocytic leukemia that has not been treated previously. Drugs used in chemotherapy, such as daunorubicin, cytarabine, mercaptopurine, methotrexate, and arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Tretinoin may help leukemia cells develop into normal white blood cells. It is not yet known which regimen is more effective for acute promyelocytic leukemia.

Clinical Trial Conditions for Mexate-aq

Condition Name

Condition Name for Mexate-aq
Intervention	Trials
Acute Lymphoblastic Leukemia	27
Untreated Adult Acute Lymphoblastic Leukemia	17
Adult Acute Myeloid Leukemia in Remission	13
B Acute Lymphoblastic Leukemia	13

Condition MeSH

Condition MeSH for Mexate-aq
Intervention	Trials
Leukemia	85
Precursor Cell Lymphoblastic Leukemia-Lymphoma	73
Leukemia, Lymphoid	73
Lymphoma	31

Clinical Trial Locations for Mexate-aq

Trials by Country

Trials by Country for Mexate-aq
Location	Trials
Canada	171
Australia	73
New Zealand	25
Puerto Rico	18
Japan	8

Trials by US State

Trials by US State for Mexate-aq
Location	Trials
Texas	64
Washington	53
California	53
Ohio	52
Pennsylvania	47

Clinical Trial Progress for Mexate-aq

Clinical Trial Phase

Clinical Trial Phase for Mexate-aq
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	32
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for Mexate-aq
Clinical Trial Phase	Trials
Completed	52
Active, not recruiting	30
Recruiting	25

Clinical Trial Sponsors for Mexate-aq

Sponsor Name

Sponsor Name for Mexate-aq
Sponsor	Trials
National Cancer Institute (NCI)	110
Children's Oncology Group	25
M.D. Anderson Cancer Center	24

Sponsor Type

Sponsor Type for Mexate-aq
Sponsor	Trials
NIH	119
Other	112
Industry	29

Methotrexate (Methotrexate-AQ): Clinical Trials, Market Analysis, and Projections

Introduction to Methotrexate (Methotrexate-AQ)

Methotrexate, often branded as Methotrexate-AQ, is a widely used medication for treating various conditions, including rheumatoid arthritis, psoriasis, and certain types of cancer. Here, we will delve into recent clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Efficacy

REFLEX Trial: Methotrexate in Rheumatoid Arthritis

One significant clinical trial involving methotrexate is the REFLEX trial, which evaluated the efficacy of rituximab (RITUXAN) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) who had an inadequate response to at least one TNF inhibitor therapy. The trial showed that patients receiving rituximab plus methotrexate had better ACR20 responses at 6 months compared to those receiving placebo plus methotrexate[1].

Tocilizumab and Methotrexate Combination

Another study compared the efficacy and safety of adding tocilizumab to methotrexate versus switching to tocilizumab monotherapy in patients with persistent active RA despite methotrexate therapy. The results indicated that both strategies achieved meaningful clinical and radiographic responses, but there was no clinically relevant superiority of the add-on strategy over the switch to tocilizumab monotherapy[4].

Market Analysis

Global Market Size and Growth

The global methotrexate drug market is projected to grow significantly over the next decade. As of 2024, the market size was valued at approximately USD 621.3 million and is expected to reach USD 1,058 million by 2034, growing at a CAGR of 5.5%[2].

Regional Market Trends

• North America: This region is expected to hold a significant revenue share, driven by high healthcare expenditures, the adoption of innovative technologies, and the availability of reimbursement policies. The market in the United States is projected to grow at a CAGR of 5.7% from 2024 to 2034[2].
• Asia-Pacific: This region is anticipated to show rapid growth due to increased technological advancements, growing healthcare expenditure, and rising awareness programs. China, for instance, is expected to progress at a CAGR of 5.9% during the forecast period[2].

End-User Segments

The hospital segment is expected to garner a significant share of the methotrexate market by 2037, driven by the increasing influx of patients with target diseases such as cancer and rheumatoid arthritis. Specialty clinics are also expected to grow at a significant rate[3].

Market Projections

Forecasted Market Size

By 2037, the global methotrexate drug market is estimated to exceed USD 846.99 million, growing at a CAGR of 2.9% from 2025 to 2037[3].

Segment Growth

• Rheumatoid Arthritis Segment: This segment is expected to register a 5.3% market CAGR from 2024 to 2034, driven by methotrexate being the recommended first-line treatment for rheumatoid arthritis according to the American College of Rheumatology[2].
• Cancer Segment: Methotrexate's use in cancer treatment is significant, with the segment expected to hold a substantial revenue share due to the rising incidence rates of various types of cancers globally[3].

Recent Developments and Trends

Innovations and New Products

Companies are investing heavily in research and development to create new and improved methotrexate products. For example, the launch of RediTrex, a prefilled syringe designed for ease of use and precise dosing for subcutaneous administration of methotrexate, has been a notable development[3].

Integrative Medicine and Value-Based Care

The rising interest in integrative medicine in the United States and the shift toward value-based care are expected to create lucrative opportunities in the methotrexate market. Integrative medicine combines traditional Western medicine with complementary therapies, which is gaining traction and driving market growth[2].

Key Statistics

• Market Size 2024: USD 621.3 million[2]
• Forecasted Market Size 2034: USD 1,058 million[2]
• CAGR 2024-2034: 5.5%[2]
• North America CAGR 2024-2034: 5.7%[2]
• Asia-Pacific CAGR 2024-2034: 5.9% (China)[2]
• Hospital Segment Growth Rate: Expected to grow with the highest CAGR of 3.3% during the forecast period[3]

Conclusion

Methotrexate remains a crucial drug in the treatment of various autoimmune diseases and cancers. The clinical trials highlight its efficacy, particularly when combined with other therapies. The market analysis indicates strong growth potential driven by increasing healthcare expenditures, technological advancements, and the rising prevalence of target diseases.

Key Takeaways

• Methotrexate is a key treatment for rheumatoid arthritis and certain cancers.
• Clinical trials such as the REFLEX trial demonstrate its efficacy in combination with other therapies.
• The global methotrexate market is projected to grow significantly, driven by regional trends and increasing healthcare expenditures.
• Innovations in product delivery and the integration of complementary therapies are expected to drive market growth.

FAQs

Q: What is the current market size of the methotrexate drug market?

The current market size of the methotrexate drug market was valued at approximately USD 621.3 million in 2024[2].

Q: What is the projected growth rate of the methotrexate market from 2024 to 2034?

The methotrexate market is expected to grow at a CAGR of 5.5% from 2024 to 2034[2].

Q: Which segment is expected to dominate the methotrexate market by 2037?

The hospital segment is expected to garner a significant share of the methotrexate market by 2037 due to the increasing influx of patients with target diseases[3].

Q: What are the key drivers of the methotrexate market growth in North America?

The key drivers include high healthcare expenditures, the adoption of innovative technologies, and the availability of reimbursement policies[2].

Q: How is the Asia-Pacific region expected to contribute to the growth of the methotrexate market?

The Asia-Pacific region, particularly China, is expected to show rapid growth due to increased technological advancements, growing healthcare expenditure, and rising awareness programs[2].

Sources

1. RITUXAN-HCP: REFLEX Clinical Trial of RITUXAN® (rituximab) in Rheumatoid Arthritis.
2. Future Market Insights: Methotrexate Drug Market Size, Share, Trends & Forecast by 2034.
3. Research Nester: Methotrexate Drugs Market Size & Share, Forecast Report 2037.
4. BMJ: Adding tocilizumab or switching to tocilizumab monotherapy in patients with rheumatoid arthritis.
5. Data Bridge Market Research: Global Methotrexate Injection Market Size, Value & Opportunities By 2030.